BXN’s Path to Growth: $28M Cannabis Deal and GMP-Certified Expansion, page-4

I agree that this stock is undervalued. The cannabis listed stocks have not had a particularly good last couple of years. My view is that most of them invested in land and crops. Effectively they are farmers- and are capital intensive- and face all the vagaries of farming- lags in production, disease ,regulation and changes in customer tastes.
BXN isn’t a farmer.
The real opportunity here in Australia is to supply the huge potential growth for gummy demand on the basis that the market share for prescribed gummies reaches the 25-30pc market share that is evidenced in Canada/USA.
This is where BXN is leading the pack.
On my calculation ,Just the announced contacts, if successfully delivered, BXN should deliver an annual gross profit margin of $8 million before overheads.
Do your own maths. I hold the stock.